Leukemia regression by vascular disruption and antiangiogenic therapy

Acute myelogenous leukemias (AMLs) and endothelial cells depend on each other for survival and proliferation. Monotherapy antivascular strategies such as targeting vascular endothelial growth factor (VEGF) has limited efficacy in treating AML. Thus, in search of a multitarget antivascular treatment...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2010-09, Vol.116 (9), p.1539-1547
Hauptverfasser:	Madlambayan, Gerard J., Meacham, Amy M., Hosaka, Koji, Mir, Saad, Jorgensen, Marda, Scott, Edward W., Siemann, Dietmar W., Cogle, Christopher R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Angiogenesis Inhibitors - therapeutic use Animals Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols Apoptosis Bevacizumab Blotting, Western Cell Proliferation Diphosphates - therapeutic use Humans Immunoenzyme Techniques Interleukin Receptor Common gamma Subunit - physiology Leukemia, Myeloid, Acute - classification Leukemia, Myeloid, Acute - pathology Leukemia, Myeloid, Acute - prevention & control Mice Mice, Inbred NOD Mice, Knockout Mice, SCID Middle Aged Myeloid Neoplasia Neovascularization, Pathologic - prevention & control Reactive Oxygen Species - metabolism Remission Induction Reverse Transcriptase Polymerase Chain Reaction RNA, Messenger - genetics Sarcoma, Myeloid - pathology Sarcoma, Myeloid - prevention & control Stilbenes - therapeutic use Tumor Cells, Cultured Vascular Endothelial Growth Factor A - antagonists & inhibitors Vascular Endothelial Growth Factor A - genetics Vascular Endothelial Growth Factor A - metabolism Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!